Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLY-200 in healthy volunteers and adults with type 2 diabetes
ACTRN12624000097549Phase 2Not yet recruiting
- Sponsor
- University of Adelaide
- Start
- Oct 2024
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of GLY-200 in type 2 diabetes mellitus (T2DM) and obesity (2 arms), sponsored by University of Adelaide. Primary endpoint: Postprandial blood glucose AUC 0-360 min. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
GLY-200
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on ACTRN12624000097549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000097549.